Brokers Offer Predictions for CLDX Q2 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at Lifesci Capital issued their Q2 2025 EPS estimates for shares of Celldex Therapeutics in a report released on Friday, June 13th. Lifesci Capital analyst S. Slutsky expects that the biopharmaceutical company will post earnings per share of ($0.85) for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Lifesci Capital also issued estimates for Celldex Therapeutics’ Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.90) EPS.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a “buy” rating and a $64.00 price target on the stock. Morgan Stanley lowered their price target on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, May 9th. UBS Group lowered their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Celldex Therapeutics in a research note on Friday, June 13th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.90.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $20.06 on Monday. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -7.43 and a beta of 1.33. The firm’s 50 day simple moving average is $19.61 and its 200 day simple moving average is $21.65. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 2,366.07% and a negative return on equity of 23.46%.

Institutional Trading of Celldex Therapeutics

Large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after acquiring an additional 680 shares in the last quarter. Invesco Ltd. grew its stake in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock worth $1,064,000 after acquiring an additional 871 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares in the last quarter. Values First Advisors Inc. grew its stake in shares of Celldex Therapeutics by 3.2% during the 1st quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company’s stock worth $550,000 after acquiring an additional 924 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after acquiring an additional 1,400 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.